Using psychedelics to treat chronic pain is understudied yet full of potential.
“In the pharmaceutical drug development community, this is what you dream about.”
One mechanism of action may be similar to taking amphetamines.
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Pain was inhibited by an α2-adrenoceptor antagonist and reduced by an α1-adrenoceptor antagonist. Opioid receptors may also be involved in the effects.
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Recent evidence suggests psychedelics may significantly improve addiction treatment outcomes.